Although the IPO market has become relatively frothy, the opportunity remains for biotech investors who carefully vet the offerings to buy great science on the cheap. This week, MacroGenics (MGNX) brings solid drug prospects, albeit in a highly competitive opportunity space. Using conservative risk discounting, I estimate the true value of the company to be $568-$628 million, or $21.85-$24.15 per share.
While MacroGenics is like many other young biotech companies in that one prospect dominates its valuation, MacroGenics also owns bona fide development platforms for further drug discovery beyond its lead compound. MacroGenics has two core scientific platforms for drug discovery: Fc-optimized antibodies and dual affinity re-targeted antibody-related molecules (DARTs).
Figure 1. Pipeline....
Only subscribers can access this article, which is part of the PRO research library covering 3,595 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: